Retrospective review of 33 referred pts w/ Recurrent fever w/ MSK & skin Sxs, assessed by NGS. NLRP1 had FMF-like Dz; NLRP recurrent fevers w/ mucocutaneous; NLRP12 periodic fevers w/ MP/EN rash; NLRC4 episodic systemic inflammation GI Sxs & atypical skin rash https://t.co/Ll2V0Uzfio

FDA has approved baricitinib (Olumiant) for the treatment of pediatric patients 12 years of age and older with severe alopecia areata https://t.co/OTXXQvNruw https://t.co/xrg5ocWyjo

Prescribing New GLP-1-Based Therapies https://t.co/cpxyxBMZ8s https://t.co/yV8Jvkh2sk

🚨 Registration opens October 1! RheumNow Live 2027 returns January 30–31 for our 9th Annual CME Meeting. 📍 Dallas + Online 📅 January 30–31, 2027 🎓 High-impact CME. Expert faculty. Real-world rheumatology. The rheumatology meeting that sets the tone for the year ahead. https://t.co/1u27pab4Ee

Amgen announced topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep (CD40L antagonist fusion protein) in adult Sjögren's dz w/ positive ESSDAI results at wk 48 https://t.co/hBKIdOE9aR https://t.co/y3tXp5xwgC

Systematic review 14 studies assessed Lung ultrasound (LUS) (vs HRCT) to detect RA-ILD (using threshold of ≥ 5 B-lines) found sensitivity was 86.8% (95% CI 80.1–91.4), specificity 75.4% (95% CI 62.3–85.1), and AUC 0.890 https://t.co/GlNpsPBwtS https://t.co/I4mITEqBI6

Study of 119 Rheum pts on GLP-1 Rx (65% T2DM, 35% obesity; mean BMI 35). @ 12 mos wt loss −7.7 kg & 56% improved ≥1 BMI category. Signif decr in A1c, FBS, lipids, LDL, TG, ESR & CRP. GLP-1RAs useful cardiometabolic benefits https://t.co/fdNtvGu8Vb~ https://t.co/vM3Ukr9XUF

Do You Have to be Overweight for GLP-1s to Work? https://t.co/7IsksT3x45 https://t.co/DaF2Dgt5Xm

TNR: Obesity Treatment & Safety https://t.co/IG3dKVWV8e https://t.co/oO1bFQa8wy

Endocrine Society - State of Obesity Science and Management The Endocrine Society has published a scientific statement reframing obesity as a heterogeneous, chronically dysregulated fat-mass disorder, whose biology is being effectively tested by GLP-1/GIP receptor agonists. Is https://t.co/FHHTNcp9gL

Lifestyle and Incretin Therapy Advice for Rheumatologists As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective reframes lifestyle counseling as an adjunct to pharmacotherapy - a https://t.co/ltPdGEgQ60

FDA FAERS pharmacovigilance study of MSK serious adverse reports w/ GLP-1 RAs - Muscle atrophy showed the strongest AE, w/ less freq reports of back pain, muscle spasms, neck pain. https://t.co/4xRH6yWH1o https://t.co/MKCKtkFd1u

2024 death rates from unintentional falls among adults≥65 yrs were 74.8/100K for men (66.6 women) Rates were higher for men > women. Fall death rates incr w/ age: highest ≥85 years. https://t.co/b4RwFHbZKj https://t.co/8m9mGUewYu